QR Code

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib

Abstract Background Thymidine kinase 1 (TK1) is a cell cycle-regulated enzyme with peak expression in the S phase during DNA synthesis, and it is an attractive biomarker of cell proliferation. Serum TK1 activity has demonstrated prognostic value in patients with early-stage breast cancer. Because cy...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Nusayba Bagegni, Shana Thomas, Ning Liu, Jingqin Luo, Jeremy Hoog, Donald W. Northfelt, Matthew P. Goetz, Andres Forero, Mattias Bergqvist, Jakob Karen, Magnus Neumüller, Edward M. Suh, Zhanfang Guo, Kiran Vij, Souzan Sanati, Matthew Ellis, Cynthia X. Ma
Hōputu: Artigo
Reo:Inglês
I whakaputaina: BMC 2017-11-01
Rangatū:Breast Cancer Research
Ngā marau:
Breast cancer
Thymidine kinase
Palbociclib
Anastrozole
Neoadjuvant
Biomarker
Urunga tuihono:http://link.springer.com/article/10.1186/s13058-017-0913-7
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite